RESUMO
AIMS: To assess markers of inflammation and bone turnover at presentation and at resolution of Charcot osteoarthropathy. METHODS: We measured serum inflammatory and bone turnover markers in a cross-sectional study of 35 people with Charcot osteoarthropathy, together with 34 people with diabetes and 12 people without diabetes. In addition, a prospective study of the subjects with Charcot osteoarthropathy was conducted until clinical resolution. RESULTS: At presentation, C-reactive protein (P = 0.007), tumour necrosis factor-α (P = 0.010) and interleukin-6 (P = 0.002), but not interleukin-1ß, (P = 0.254) were significantly higher in people with Charcot osteoarthropathy than in people with and without diabetes. Serum C-terminal telopeptide (P = 0.004), bone alkaline phosphatase (P = 0.006) and osteoprotegerin (P < 0.001), but not tartrate-resistant acid phosphatase (P = 0.126) and soluble receptor activator of nuclear factor-κß ligand (P = 0.915), were significantly higher in people with Charcot osteoarthropathy than in people with and without diabetes. At follow-up it was found that tumour necrosis factor-α (P = 0.012) and interleukin-6 (P = 0.003), but not C-reactive protein (P = 0.101), interleukin-1ß (P = 0.457), C-terminal telopeptide (P = 0.743), bone alkaline phosphatase (P = 0.193), tartrate-resistant acid phosphatase (P = 0.856), osteoprotegerin (P = 0.372) or soluble receptor activator of nuclear factor-kß ligand (P = 0.889), had significantly decreased between presentation and the 3 months of casting therapy time point, and all analytes remained unchanged from 3 months of casting therapy until resolution. In people with Charcot osteoarthropathy, there was a positive correlation between interleukin-6 and C-terminal telopeptide (P = 0.028) and tumour necrosis factor-α and C-terminal telopeptide (P = 0.013) only at presentation. CONCLUSIONS: At the onset of acute Charcot foot, serum concentrations of tumour necrosis factor-α and interleukin-6 were elevated; however, there was a significant reduction in these markers at resolution and these markers may be useful in the assessment of disease activity.
Assuntos
Artropatia Neurogênica/terapia , Reabsorção Óssea/prevenção & controle , Colágeno Tipo I/sangue , Diabetes Mellitus Tipo 1/complicações , Diabetes Mellitus Tipo 2/complicações , Regulação para Baixo , Interleucina-6/sangue , Peptídeos/sangue , Adulto , Idoso , Artropatia Neurogênica/sangue , Artropatia Neurogênica/complicações , Artropatia Neurogênica/fisiopatologia , Biomarcadores/sangue , Reabsorção Óssea/etiologia , Estudos de Coortes , Estudos Transversais , Humanos , Imobilização , Mediadores da Inflamação/sangue , Estudos Longitudinais , Pessoa de Meia-Idade , Estudos Prospectivos , Indução de Remissão , Regulação para CimaRESUMO
This study evaluated the concentrations of α-tocopherol, ß-carotene, creatine, carnosine, anserine and coenzyme Q10 in Longissimus dorsi (Ld) and Gluteus medius (Gm) muscles of culled dairy cows and the impact of age, production status before slaughter (dry-off vs lactating) and carcass weight on them. The effects of applying a finishing feeding regimen before slaughter were also examined. Gm muscle presented higher levels (P<0.001) of α-tocopherol (5.14 vs 3.61 µg · g(-1)) ß-carotene (0.36 vs 0.27 µg · g(-1)), anserine (59.24 vs 43.25 mg · 100 g(-1)) and coenzyme Q10 (3.33 vs 1.73 mg · 100 g(-1)), and by contrast lower (P<0.05) creatine concentration (502.40 vs 527.28 mg · 100 g(-1)) than Ld. Dry-off and lactating cows differed significantly in α-tocopherol level (P<0.001) but not in the concentrations of the other compounds (P>0.05). The finishing feeding promoted higher mean concentrations of anserine and creatine but lower carnosine values (P>0.05) than directly slaughtered dry-off cows. The variation between muscles and from animal-to-animal makes it difficult to exactly define the antioxidant status of the dairy cow's meat.
Assuntos
Antioxidantes/análise , Carne/análise , Músculo Esquelético/química , Ração Animal/análise , Animais , Anserina/análise , Açores , Peso Corporal , Carnosina/análise , Bovinos , Creatina/análise , Dieta/veterinária , Feminino , Qualidade dos Alimentos , Lactação , Ubiquinona/análogos & derivados , Ubiquinona/análise , alfa-Tocoferol/análise , beta Caroteno/análiseRESUMO
BACKGROUND: Obesity is associated with hypertension, but the exact mechanism is not fully understood. Bariatric surgery significantly decreases weight and blood pressure (BP). Low plasma nitric oxide (NO) and raised asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO, concentrations are associated with both obesity and hypertension. Correlations between the changes in these parameters were studied after bariatric surgery. METHODS: Weight, BP, plasma ADMA and NO were measured in 29 obese patients (24 female, 5 male) before and six weeks after bariatric surgery. RESULTS: Patients were 39.2 ± 1.2 (mean ± SEM) years old and weighed 126 ± 3 kg. Six weeks after the surgery, patients had lost 10 ± 0.7 kg (P < 0.0001) and mean arterial pressure (MAP) decreased by 11 ± 1.0 mmHg (P < 0.0001). The plasma ADMA concentration decreased by 24 ± 2% from 5 ± 0.4 to 4.0 ± 0.3 µmol/L (P < 0.0001). The plasma total nitrite concentration increased by 15 ± 1% from 51.4 ± 2.6 to 60 ± 3 µmol/L (P < 0.0001). The correlation between the decrease of ADMA and increase of NO subsequent to weight loss was significant (P < 0.0001). However, MAP was not correlated to the changes in ADMA or NO. CONCLUSIONS: After bariatric surgery, beneficial changes in BP, NO and ADMA occur, but our findings suggest that these BP changes are independent of changes in the NO-ADMA axis. Other causes for the changes in BP should therefore be considered.
Assuntos
Arginina/análogos & derivados , Cirurgia Bariátrica , Pressão Sanguínea , Óxido Nítrico/sangue , Arginina/sangue , Feminino , Humanos , Masculino , Obesidade Mórbida/cirurgia , Redução de PesoRESUMO
BACKGROUND: Crohn's disease is associated with reduced bone density. The power of simple markers of systemic inflammation to identify higher rates of bone loss, in Crohn's disease, is uncertain. This relationship and the role of circulating (peripheral blood) mononuclear cells were investigated in a case-control study. METHODS: Urinary deoxypyridinoline/creatinine and serum osteocalcin concentrations were compared in male and premenopausal females with "active" Crohn's disease (C-reactive protein > or = 10 and/or erythrocyte sedimentation rate > or = 20) (n = 22) and controls with "quiescent" Crohn's disease (C-reactive protein < 10 and erythrocyte sedimentation rate < 20) (n = 21). No patients were receiving corticosteroid therapy. Production of tumour necrosis factor-alpha, interferon-gamma and prostaglandin E(2) by peripheral blood mononuclear cells were measured. RESULTS: Active Crohn's disease was associated with a higher deoxypyridinoline/creatinine (P = 0.02) and deoxypyridinoline/creatinine:osteocalcin ratio (P =0.01) compared with quiescent Crohn's disease, but similar osteocalcin (P = 0.24). These were not explained by vitamin D status, dietary intake or nutritional status. However, production of interferon-gamma by concanavalin A-stimulated peripheral blood mononuclear cells was lower in active Crohn's disease (P = 0.02) and correlated negatively with the deoxypyridinoline/creatinine:osteocalcin ratio (r = -0.40, P = 0.004). CONCLUSION: In Crohn's disease, raised C-reactive protein and erythrocyte sedimentation rate may indicate higher rates of bone loss and, if persistent, the need to assess bone mass even where disease symptoms are mild. This may be partly explained by altered production of interferon-gamma by peripheral blood mononuclear cells.
Assuntos
Remodelação Óssea/fisiologia , Proteína C-Reativa/análise , Doença de Crohn/fisiopatologia , Adulto , Sedimentação Sanguínea , Reabsorção Óssea/fisiopatologia , Estudos de Casos e Controles , Citocinas/metabolismo , Feminino , Humanos , Masculino , Estado Nutricional , Osteocalcina/metabolismo , Prostaglandinas/metabolismoRESUMO
OBJECTIVE: To investigate skeletal growth and bone metabolism in a chronic animal model of urinary diversion. MATERIALS AND METHODS: Young male Wistar rats (120) were allocated randomly to four groups undergoing: ileocystoplasty, ileocystoplasty and resection of the ileocaecal segment, colocystoplasty, and controls. All animals received antibiotics for 1 week after surgery; half of each group remained on oral antibiotics. Bone-related biochemistry was measured in serum and urine. Dual-energy X-ray absorptiometry and peripheral quantitative computed tomography (pQCT) were used to determine bone mass ex vivo. RESULTS: Most (90%) of the rats survived the study period (8 months); six rats died from bowel obstruction at the level of the entero-anastomosis and four had to be killed because of persistent severe diarrhoea. Vital intestinal mucosa was found in all augmented bladders. There were no differences in bone length and volume. Loss of bone mass was almost exclusively in rats with ileocystoplasty and resection of the ileocaecal segment (-37.5%, pQCT, P < 0.01). There was no hyperchloraemic metabolic acidosis or gross impairment of renal function. Hypomagnesaemia, hypocalcaemia and decreased insulin-like growth factor-binding protein 3 were the only significant findings on blood analysis. Deoxypyridinoline crosslinks in urine were higher in rats with an enterocystoplasty than in controls. CONCLUSIONS: Enterocystoplasty in rats neither impairs skeletal growth nor bone quantity, but leads to significant loss of bone mass when combined with resection of the ileocaecal segment. Rarefaction of the trabecular network is confined to the metabolically highly active cancellous compartment, most likely as a consequence of intestinal malabsorption.
Assuntos
Desenvolvimento Ósseo/fisiologia , Remodelação Óssea/fisiologia , Osso e Ossos/metabolismo , Bexiga Urinária/cirurgia , Absorciometria de Fóton , Animais , Densidade Óssea , Creatinina/sangue , Eletrólitos/sangue , Enzimas/sangue , Masculino , Ratos , Ratos Wistar , Albumina Sérica/análise , Derivação UrináriaRESUMO
AIM: To establish whether bone disease is present at diagnosis in inflammatory bowel disease and to identify contributory metabolic abnormalities. METHODS: Newly diagnosed patients with inflammatory bowel disease (19 males, 15 females; mean age, 44 years; range, 17-79 years; 23 ulcerative colitis, 11 Crohn's disease) were compared against standard reference ranges and a control group with irritable bowel syndrome (eight males, 10 females; mean age, 40 years; range, 19-64 years). Bone mineral density (g/cm2, dual-energy X-ray absorptiometry: lumbar spine and femoral neck) and biochemical bone markers were measured. RESULTS: Femoral neck bone mineral density, T- and Z-scores (mean +/- s.d., respectively) were lower in inflammatory bowel disease patients than in irritable bowel syndrome controls (0.78 +/- 0.12 vs. 0.90 +/- 0.16, P = 0.0046; - 0.88 +/- 0.92 vs. 0.12 +/- 1.17, P = 0.0018; - 0.30 +/- 0.89 vs. 0.61 +/- 1.10, P = 0.0030). Lumbar spine bone mineral density and T-scores were also significantly lower in patients than controls (0.98 +/- 0.15 vs. 1.08 +/- 0.13, P = 0.0342; - 1.05 +/- 1.39 vs. - 0.14 +/- 1.19, P = 0.0304). Compared with controls, the urinary deoxypyridinoline : creatinine ratio was increased (7.66 vs. 5.70 nmol/mmol, P = 0.0163) and serum 25-hydroxy vitamin D was decreased (18.7 vs. 28.5 micro g/L, P = 0.0016); plasma osteocalcin and serum parathyroid hormone did not differ (P > 0.05). CONCLUSIONS: The bone mineral density is reduced at diagnosis, prior to corticosteroid treatment, in both Crohn's disease and ulcerative colitis. Our data suggest that this is attributable to increased resorption rather than decreased bone formation.
Assuntos
Doenças Ósseas Metabólicas/etiologia , Doenças Inflamatórias Intestinais/complicações , Adolescente , Adulto , Idoso , Biomarcadores/análise , Densidade Óssea , Doenças Ósseas Metabólicas/fisiopatologia , Estudos de Casos e Controles , Colite Ulcerativa/complicações , Colite Ulcerativa/fisiopatologia , Doenças Funcionais do Colo/complicações , Doenças Funcionais do Colo/fisiopatologia , Doença de Crohn/complicações , Doença de Crohn/fisiopatologia , Feminino , Colo do Fêmur/fisiopatologia , Humanos , Doenças Inflamatórias Intestinais/fisiopatologia , Vértebras Lombares/fisiopatologia , Masculino , Pessoa de Meia-IdadeRESUMO
We report the development of an assay for measurement of the urinary concentration of collagen type II C-telopeptide fragments. This assay was developed for providing a specific marker of joint metabolism. A monoclonal antibody, recognizing a linear six amino acid epitope from the middle region of the collagen type II C-telopeptide was used in a competitive enzyme-linked immunoassay (ELISA) format for measurement of urine samples. The technical performance and specificity of the assay was evaluated and a panel of samples from patients with rheumatoid arthritis (RA) (n = 27), osteoarthritis (OA) (n = 29), Paget's disease (n = 9), and healthy controls (n = 428) was measured in the assay. The ELISA was specific for the peptide EKGPDP derived from collagen type II C-telopeptide: it did not recognize peptides from the N-telopeptide of the molecule or from other collagen types. Collagen type II C-telopeptide fragments measured in the assay resisted seven freeze-thaw cycles and >20 h of storage at room temperature. RA and OA patients showed significant 2.33-fold (95% confidence interval [CI] 1.50-3.16) and 1.53-fold (CI 1.24-1.82) elevations in CartiLaps concentration, respectively. Paget's disease patients did not have elevated CartiLaps levels. RA patients with radiological evidence of cartilage damage had significantly higher (1.79-fold, CI 1.04-2.54) CartiLaps levels than RA patients without radiological evidence of cartilage destruction. The Cartilaps assay showed high technical precision and an ability to differentiate populations with an elevated joint metabolism from normal controls. This suggests that the assay may have clinical value in assisting in the diagnosis of joint diseases and in monitoring progression and therapy in RA and OA.
Assuntos
Artrite Reumatoide/urina , Cartilagem/patologia , Colágeno Tipo II/análise , Osteoartrite/urina , Animais , Anticorpos Monoclonais , Especificidade de Anticorpos , Artrite Reumatoide/patologia , Biomarcadores , Células Cultivadas , Ritmo Circadiano , Colágeno/análise , Colágeno/imunologia , Colágeno/urina , Colágeno Tipo I , Colágeno Tipo II/imunologia , Colágeno Tipo II/urina , Ensaio de Imunoadsorção Enzimática , Feminino , Técnicas In Vitro , Camundongos , Camundongos Endogâmicos BALB C , Osteíte Deformante/patologia , Osteíte Deformante/urina , Osteoartrite/patologia , Osteoclastos/química , Osteoclastos/citologia , Fragmentos de Peptídeos/análise , Fragmentos de Peptídeos/imunologia , Fragmentos de Peptídeos/urina , Peptídeos/análise , Peptídeos/imunologia , Peptídeos/urina , CoelhosRESUMO
BACKGROUND AND OBJECTIVES: Familial hyperparathyroidism may occur as familial isolated hyperparathyroidism (FIHP) or as part of an inherited syndrome, in particular multiple endocrine neoplasia types 1 and 2A (MEN1, MEN2A) and hyperparathyroidism-jaw tumour (HPT-JT) syndrome. The localization of the genes responsible for these syndromes has enabled genetic screening of families with primary hyperparathyroidism (PHPT) to be carried out. This has important clinical implications in terms of individual follow-up and management. We previously reported a large FIHP family with an increased risk of parathyroid cancer and excluded its linkage to MEN1, MEN2 and PTH genes. Here we re-analysed this family and performed genetic linkage to the HPT-JT locus in chromosome 1q21-q32. Loss of heterozygosity studies of 1q21-q32, 11q13 and X chromosome were also performed. PATIENTS AND DESIGN: We studied 19 family members, aged 6-63 years. High molecular weight DNA was isolated from peripheral blood samples from 17 family members. For the two deceased individuals, DNA was extracted from normal paraffin embedded tissues. MEASUREMENTS: All individuals (except two deceased patients) had serum corrected calcium, inorganic phosphate, intact PTH, prolactin and various pancreatic hormones, measured on fasting blood samples. Twenty microsatellite markers were examined for the 1q21-q32 region, the locus for the HPT-JT gene. Genetic polymorphisms were determined by polymerase chain reaction amplification of genomic DNA and genetic linkage analysis was performed. Loss of heterozygosity studies were performed using paraffin-embedded parathyroid tissues from four affected members. RESULTS: Seven of the eight affected family members included in this study had biochemical evidence of PHPT and surgically proven parathyroid tumours. Indication of linkage of the disease to the HPT-JT locus was demonstrated with a maximum lod score of 2.32 by two-points linkage analysis. Linkage data were supported by multi-point analysis which gave a maximum lod score of 2.7. Meiotic recombinations detected in one affected individual narrowed the region to 26 cM. As a result of the genetic findings, we re-screened the living family members by orthopantomograph and renal ultrasound, and identified two jaw lesions in two gene carriers. One affected family member demonstrated polycystic kidney disease, thus establishing the association between the two conditions. A reduced penetrance of HPT in females was evident, in agreement with our previous study. No allelic deletion was detected in any tumour at 1q21-q32, 11q13 or X chromosome. CONCLUSIONS: This study illustrates the usefulness and importance of genetic studies in familial isolated hyperparathyroidism families. Our clinical and genetic findings indicate that this previously reported familial isolated hyperparathyroidism family has hyperparathyroidism-jaw tumour syndrome.
Assuntos
Cromossomos Humanos Par 1 , Ligação Genética , Hiperparatireoidismo/genética , Neoplasias Maxilomandibulares/genética , Adolescente , Adulto , Criança , Feminino , Humanos , Neoplasias Maxilomandibulares/diagnóstico , Escore Lod , Perda de Heterozigosidade , Masculino , Pessoa de Meia-Idade , Linhagem , SíndromeRESUMO
OBJECTIVE: Polymyalgia rheumatica (PMR) has an abrupt onset of inflammatory symptoms, making it a useful model for studying the effects of inflammation in bone. PMR requires corticosteroid treatment, which may itself have a detrimental effect on bone. This study used serially measured biochemical markers of bone turnover and bone density to address the relative contributions of systemic inflammation and corticosteroid therapy to bone loss. METHODS: Fifty untreated patients with PMR were randomized to receive oral prednisolone or intramuscular methylprednisolone. Biochemical bone markers (pyridinoline [PYR], deoxypyridinoline [DPYR], procollagen type I carboxy-terminal peptide [PICP]) and bone mineral density (BMD) were measured at baseline and at 6, 12, and 24 months. RESULTS: The median disease duration at presentation was 12 weeks (range 5-32 weeks). Levels of urinary crosslinks were increased in patients with untreated PMR compared with controls (PYR 74.9 +/- 30.0 nmoles/mmole creatinine, DPYR 14.6 +/- 6.4 nmoles/mmole creatinine [mean +/- SD]; P = 0.0001); the PICP level was normal (115.0 +/- 39.0 microg/liter). With treatment, the crosslinks levels fell and PICP levels rose within 6 months (P = 0.01). Bone resorption (PYR) correlated with untreated disease activity (erythrocyte sedimentation rate [ESR]) (r = 0.5, P = 0.003) and with interleukin-6 levels (r = 0.48, P = 0.05). There was a significant reduction in BMD of both the hip and the spine after 12 months of treatment (P = 0.0002), with no difference between treatment groups. As the steroid dosage was reduced, bone mass improved. Initial ESR influenced the percent change in BMD at 1 year (r = 0.35, P = 0.05), while cumulative steroid dose, mean ESR, and type of steroid used did not. CONCLUSION: Inflammation in PMR increases bone resorption and appears to have a more detrimental effect on bone than does low-dose corticosteroid. If corticosteroids can be tapered and discontinued, bone loss in PMR can be a transient phenomenon.
Assuntos
Corticosteroides/uso terapêutico , Densidade Óssea/fisiologia , Remodelação Óssea/fisiologia , Inflamação/fisiopatologia , Polimialgia Reumática/tratamento farmacológico , Polimialgia Reumática/fisiopatologia , Corticosteroides/administração & dosagem , Idoso , Idoso de 80 Anos ou mais , Aminoácidos/análise , Biomarcadores/análise , Feminino , Humanos , Injeções Intramusculares , Interleucina-6/metabolismo , Masculino , Metilprednisolona/administração & dosagem , Metilprednisolona/uso terapêutico , Pessoa de Meia-Idade , Fragmentos de Peptídeos/análise , Polimialgia Reumática/metabolismo , Prednisolona/administração & dosagem , Prednisolona/uso terapêutico , Pró-Colágeno/análise , Estudos ProspectivosRESUMO
Calcium intake and physical activity level (PAL) were assessed by questionnaire in 124 healthy women aged 52-62 y to determine the effect of calcium intake and PAL on bone mass and turnover. Four groups were identified according to their different reported calcium intakes and PALs. Bone mineral density (BMD) at the spine, hip, and left os calcis was measured together with total bone mineral content (TBMC) with dual-energy X-ray absorptiometry. Bone formation and resorption biochemical markers were measured in fasting samples of blood and urine. Women with the highest calcium intakes and PALs had the highest BMD at all sites compared with those with the lowest calcium intakes and PALs (P < 0.001). Calcium intake and PAL were positively correlated with BMD at all sites. Bone turnover markers did not explain the variation in bone mass between groups. In stepwise-multiple-regression analysis only calcium intake, physical activity, age, or weight remained as independent predictors of BMD and TBMC. When subjects were divided by past PALs, calcium intake and PAL were second to age and weight in their influence on spinal and hip BMD, but remained influential on the os calcis and whole body. We conclude that current high calcium intakes and PALs influence BMD at the os calcis and TBMC and protect bone mass in women 5-12 y postmenopausal at all measured sites, including the spine and hip. This finding does not exclude the possibility of past influences of calcium and activity on bone mass.
Assuntos
Densidade Óssea , Cálcio da Dieta/administração & dosagem , Aptidão Física , Pós-Menopausa/fisiologia , Biomarcadores/sangue , Biomarcadores/urina , Cálcio da Dieta/metabolismo , Estudos de Coortes , Feminino , Humanos , Pessoa de Meia-Idade , Osteoporose/prevenção & controle , Pós-Menopausa/sangue , Pós-Menopausa/urina , Análise de Regressão , Inquéritos e QuestionáriosRESUMO
BACKGROUND: Reduced bone mineral density in patients with inflammatory bowel disease is thought to be due to disturbances in calcium homeostasis or the effects of corticosteroid treatment. AIMS: To assess the prevalence and mechanism of reduced bone mineral density in 79 patients with inflammatory bowel disease (44 with Crohn's disease, 35 with ulcerative colitis) who did not have significant risk factors for low bone densities. METHODS: Dual x ray absorptiometry was used to measure bone mineral density and serum and urinary markers of osteoblast (alkaline phosphatase, procollagen 1 carboxy terminal peptide and osteocalcin) and osteoclast (pyridinoline, deoxypyridinoline, and type 1 collagen carboxy terminal peptide) activities to assess bone turnover. RESULTS: There was a high prevalence of low bone mineral density (prevalence of T scores < -1.0 from 51%-77%; T scores < -2.5 (osteoporosis) from 17%-28%) with hips being more often affected than vertebrae (p < 0.001). Reduced bone mineral density did not relate to concurrent or past corticosteroid intake, or type, site, or severity of disease. Whereas calcium homeostasis was normal, bone markers showed increased bone resorption without a compensatory increase in bone formation. CONCLUSIONS: The greater prevalence of reduced hip bone mineral density, as opposed to vertebral, mineral density and the pattern of a selective increase in bone resorption contrasts with that found in other known causes of metabolic bone disease.
Assuntos
Densidade Óssea , Reabsorção Óssea , Colite Ulcerativa/fisiopatologia , Doença de Crohn/fisiopatologia , Absorciometria de Fóton , Adulto , Idoso , Fosfatase Alcalina/sangue , Aminoácidos/urina , Anti-Inflamatórios/uso terapêutico , Colite Ulcerativa/metabolismo , Doença de Crohn/tratamento farmacológico , Doença de Crohn/metabolismo , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Osteocalcina/sangue , Ossos Pélvicos/fisiopatologia , Fragmentos de Peptídeos/sangue , Prednisolona/uso terapêutico , Prevalência , Pró-Colágeno/sangue , Coluna Vertebral/fisiopatologiaRESUMO
We have used a 5' regulatory sequence fragment of the human parathyroid hormone-related peptide (PTHrP) gene to identify nuclear DNA-binding proteins (DBP), using South-Western analysis. The PTHrP 549 bp DNA fragment was amplified from a human genomic DNA, and composed of 5' non-coding exon Ic, the intervening intron and 5' non-coding exon II. The DNA fragment bound very specifically to a 70 kDa and a 65 kD protein from the nuclear extract of human hepatocyte, HepG2, and keratinocyte, SVK-14, cell lines. This is the first evidence of a physical binding between nuclear protein and the human PTHrP gene. The 70 kDa and 65 kDa nuclear proteins may have a role in the regulation of human PTHrP gene expression.
Assuntos
Proteínas Nucleares/metabolismo , Hormônio Paratireóideo/genética , Regiões Promotoras Genéticas , Proteínas/genética , Sequência de Bases , Primers do DNA , Proteínas de Ligação a DNA/genética , Proteínas de Ligação a DNA/metabolismo , Humanos , Dados de Sequência Molecular , Hormônio Paratireóideo/metabolismo , Proteína Relacionada ao Hormônio Paratireóideo , Ligação Proteica , Proteínas/metabolismoRESUMO
PROBLEM: A discrepancy exists between the apparently normal ovulation and the pregnancy rates in women treated with clomiphene citrate (CC). Our previous studies have indicated that immuno-suppressive "early pregnancy factor" (EPF) is a novel marker to detect subclinical embryonic loss in infertile women. METHOD: In the present study EPF was used as a marker to detect subclinical embryonic loss in women treated with CC with/without gonadotropins. In some of the women treated with CC, conception was assisted by artificial insemination with husband's semen (AIH). RESULTS: Our results have indicated that fertilization occurred (EPF + ve) in 47.7% (52/109) of women treated with CC with/without gonadotropins; 13.46% (7/52) retained the fetus and continued pregnancy till full term, whereas 78.9% (41/52) did not retain the fetuses. In the group where after stimulation, conception was assisted by AIH, fertilization was observed in 38.24% (26/68), retention in 11.54% (3/26) but subclinical embryonic loss was observed in 80.8% (21/26) cases. CONCLUSION: Thus, our results have indicated that subclinical embryonic loss may account for some of the discrepancy observed between the apparently normal ovulation and the pregnancy rates in women treated with clomiphene citrate.
Assuntos
Clomifeno/uso terapêutico , Fármacos para a Fertilidade Feminina/uso terapêutico , Morte Fetal/diagnóstico , Imunossupressores/análise , Peptídeos/análise , Proteínas da Gravidez , Fatores Supressores Imunológicos , Adulto , Biomarcadores/análise , Chaperonina 10 , Feminino , Gonadotropinas/uso terapêutico , Humanos , Indução da Ovulação , Gravidez , Método Simples-CegoRESUMO
Carboxyterminal propeptide of type I procollagen (PICP) was measured in sera from 25 patients with osteomalacia due to privational vitamin D deficiency. The mean value of serum PICP was significantly raised in patients with osteomalacia compared with 40 normal subjects (mean +/- SD, 161 +/- 82 ng/ml and 113 +/- 31 ng/ml, respectively; P = 0.01). The raised serum PICP reflected the accelerated bone turnover in this condition as did the elevated serum total alkaline phosphatase (ALP), but the variation in values of serum PICP noted in individual patients may reflect the different stages of osteomalacia. The normalization of serum PICP and ALP, indicating a healing process of the bone disorder, needed longer time of vitamin D and calcium therapy. In contrast, adjusted serum calcium and inorganic phosphate (IP) responded and normalized rapidly. Serum PICP and total ALP appeared to behave differently in the disease and in its response to vitamin D therapy suggesting that these two markers may represent different functions of osteoblasts in osteomalacia.
Assuntos
Osteomalacia/sangue , Fragmentos de Peptídeos/sangue , Pró-Colágeno/sangue , Adulto , Idoso , Fosfatase Alcalina/sangue , Biomarcadores/sangue , Cálcio/sangue , Cálcio da Dieta/administração & dosagem , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Osteoblastos/metabolismo , Osteomalacia/tratamento farmacológico , Osteomalacia/etiologia , Vitamina D/uso terapêuticoRESUMO
The concentrations of plasma parathyroid hormone-like bioactivity and parathyroid hormone-related protein (1-86) (PTHrP) immunoreactivity were both higher in fetal pigs than in their mothers during the last 3 weeks of gestation. Both activities changed inversely with alterations in the plasma ionized calcium concentration. The data suggest that PTHrP may have a role in calcium homeostasis in the fetal pig, similar to its postulated role in sheep in the stimulation of calcium transport across the placenta.
Assuntos
Cálcio/metabolismo , Feto/metabolismo , Hipercalcemia/induzido quimicamente , Hormônio Paratireóideo/sangue , Placenta/metabolismo , Proteínas/metabolismo , Animais , Cálcio/sangue , Ácido Edético/farmacologia , Feminino , Feto/efeitos dos fármacos , Homeostase , Transporte de Íons , Proteína Relacionada ao Hormônio Paratireóideo , Gravidez , SuínosRESUMO
Seventeen patients suffering from early rheumatoid disease (mean duration, 3.5 years) and treated with nonsteroidal antiinflammatory drugs alone had evidence of systemic bone changes. Transiliac bone biopsies, compared with age and gender-matched controls, demonstrated reduced bone volume and increased eroded surface. In addition, the metacarpal indices were reduced in the rheumatoid patients and correlated with the iliac crest bone volume. These changes, found distal from sites of synovitis, suggest that in this group of rheumatoid patients there were systemic changes of bone metabolism. No biochemical abnormalities of calcium homeostasis were found. Collectively, present observations may be a reflection of the rheumatoid disease process itself.
Assuntos
Artrite Reumatoide/patologia , Osso e Ossos/patologia , Adulto , Idoso , Anti-Inflamatórios não Esteroides/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/fisiopatologia , Biópsia , Matriz Óssea/química , Remodelação Óssea , Osso e Ossos/metabolismo , Cálcio/metabolismo , Creatinina/urina , Feminino , Homeostase , Humanos , Hidroxiprolina/urina , Ílio/patologia , Masculino , Pessoa de Meia-Idade , Sinovite/fisiopatologiaRESUMO
It is now well recognized that the presence of early pregnancy factor (EPF) can signify the occurrence of fertilization, continuation of pregnancy and the existence of a viable embryo. With this in view, a study was undertaken to observe the potential of EPF as a marker in assessing embryo viability in cases complicated with vaginal bleeding during early pregnancy. The results indicated that the sensitivity of EPF as a marker in predicting threatened or missed abortion was 78.9% and the specificity 95.6%. The positive predictive value was observed to be 93.8% and the negative predictive value 84.6%. Our studies have shown that since EPF is present in viable but absent in non-viable pregnancies, it could be a useful marker of prognostic value in threatened abortions.
Assuntos
Aborto Retido/sangue , Ameaça de Aborto/sangue , Viabilidade Fetal , Peptídeos/sangue , Proteínas da Gravidez , Fatores Supressores Imunológicos , Adulto , Biomarcadores/sangue , Chaperonina 10 , Feminino , Humanos , Gravidez , Sensibilidade e Especificidade , Método Simples-CegoRESUMO
Familial isolated hyperparathyroidism (FIHP) is a rare heritable disorder characterized by hypercalcemia, inappropriately high PTH levels, and isolated parathyroid tumors with no evidence of hyperfunction of any other endocrine tissues. To establish whether FIHP exists as a distinct disease entity or represents a variant of any of the known multiple endocrine neoplasia (MEN) syndromes, we tested 19 members of a large, well characterized family with FIHP in which the disease is transmitted through 4 generations in an autosomal dominant fashion. Fourteen DNA markers at 10 polymorphic loci closely linked to the MEN1 locus on the long arm of chromosome 11 and 5 markers close to the MEN2A gene on chromosome 10 were tested using Southern blot analysis and polymerase chain reaction-based techniques. Additionally, two polymorphic markers (Mir1 and Mir2) within the prepro-PTH gene on the short arm of chromosome 11 were analyzed using denaturant gradient gel electrophoresis. Linkage was clearly excluded between FIHP and the MEN1 and MEN2A loci as well as to the PTH gene. Comparison of constitutional and tumor genotypes showed that constitutional heterozygosity was retained for markers in the MEN1 and MEN2A regions as well as to the PTH gene in 4 tumors from 3 affected members. In 1 individual, a parathyroid carcinoma was found after recurrence of hypercalcemia. We, therefore, propose that autosomal dominant FIHP can occur as a genetically and clinically distinct entity with an increased risk of malignant transformation of parathyroid tumors.
Assuntos
Hiperparatireoidismo/genética , Neoplasias das Paratireoides/etiologia , Adolescente , Adulto , Criança , Feminino , Ligação Genética , Humanos , Hiperparatireoidismo/complicações , Masculino , Pessoa de Meia-Idade , Neoplasia Endócrina Múltipla/genética , Hormônio Paratireóideo/genética , Linhagem , RiscoRESUMO
Biochemical markers of bone turnover were measured in fasting urine and blood samples obtained from 38 postmenopausal women with previous surgical treatment of breast cancer combined with adjuvant chemotherapy, tamoxifen, or placebo. Significantly elevated urinary pyridinoline as nmol mmol-1 creatinine (47.5 and 42.5 in tamoxifen and placebo treated patients compared with 26.3 in normal controls, both P < 0.001) and deoxypyridinoline (11.9 and 10.5 compared with 6.3, P < 0.001 and P = 0.002 respectively) were found with unchanged urinary hydroxyproline, serum alkaline phosphatase and procollagen I carboxyterminal peptide (PICP). These findings suggest enhanced bone resorption resulting from the humoral osteoclast activating effect of the previous breast cancer or underlying carcinoma recurrence. Alternatively the raised pyridinium excretion might indicate an altered crosslinking composition of bone collagen. No specific effect on bone metabolism was found with tamoxifen treatment as all measured parameters were similar in both tamoxifen ex-users and non-users. This confirmed the safety of tamoxifen therapy with respect to bone.